KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer | Zendy

Ken Kato | Zendy; Manish A. Shah | Zendy; Peter C. Enzinger | Zendy; Jaafar Bennouna | Zendy; Lin Shen | Zendy; Antoine Adenis | Zendy; JongMu Sun | Zendy; Byoung Chul Cho | Zendy; Mustafa Özgüroğlu | Zendy; Takashi Kojima | Zendy; Vladimir Kostorov | Zendy; Cinta Hierro | Zendy; Ying Zhu | Zendy; Lee Anne McLean | Zendy; Sukrut Shah | Zendy; Toshihiko Doi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer

Author(s) -

Ken Kato,

Manish A. Shah,

Peter C. Enzinger,

Jaafar Bennouna,

Lin Shen,

Antoine Adenis,

JongMu Sun,

Byoung Chul Cho,

Mustafa Özgüroğlu,

Takashi Kojima,

Vladimir Kostorov,

Cinta Hierro,

Ying Zhu,

Lee Anne McLean,

Sukrut Shah,

Toshihiko Doi

Publication year - 2019

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2018-0609

Subject(s) - pembrolizumab , medicine , esophageal cancer , chemotherapy , oncology , cancer , immunotherapy

Background: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Aim: To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. Clinical trial registry & ID: ClinicalTrials.gov : NCT03189719.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research